Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Liming Sheng ◽  
Min Luo ◽  
Xiaojiang Sun ◽  
Nengming Lin ◽  
Weimin Mao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Independent Prognostic Factor

scholarly journals Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer

Cancer ◽  
2006 ◽  
Vol 107 (5) ◽  
pp. 1042-1049 ◽  
Author(s):  
Hojoong Kim ◽  
Young Mi Kwon ◽  
Jin Seuk Kim ◽  
Joungho Han ◽  
Young Mog Shim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Cell Lung Cancer ◽  
Dna Methyltransferase ◽  
Nonsmall Cell Lung Cancer ◽  
Independent Prognostic Factor ◽  
Dna Methyltransferase 1 ◽  
Mrna Levels ◽  
Methyltransferase 1

Tumor Location Is Not an Independent Prognostic Factor in Early Stage Non-Small Cell Lung Cancer

2010 ◽  
Vol 89 (4) ◽  
pp. 1053-1059 ◽  
Author(s):  
Varun Puri ◽  
Nitin Garg ◽  
Erin E. Engelhardt ◽  
Daniel Kreisel ◽  
Traves D. Crabtree ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Tumor Location ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
Small Cell Lung

scholarly journals Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000823
Author(s):  
Yan Xu ◽  
Ji Li ◽  
Bing Tong ◽  
Minjiang Chen ◽  
Xiaoyan Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Infectious Diseases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
Small Cell Lung ◽  
Cox Regression Analysis ◽  
Resected Nsclc

BackgroundImmunotherapy is a promising advance in oncology. Limited information exists regarding the interrelationship between CD47 expression and tumour-associated macrophage-related immuno-microenvironment in patients with non-small cell lung cancer (NSCLC). These factors may predict novel immunotherapy efficacy.Patients and methodsCD47 and PD-L1 expression was retrospectively assessed in 191 resected NSCLC specimens via immunohistochemistry. Forty-six patients with pulmonary infectious diseases were enrolled as the control group. The infiltration of macrophages (M2 and M1) and CD8+ T-lymphocytes was evaluated via dual-immunofluorescence staining. Targeted DNA sequencing was performed on NSCLC specimens. Survival analysis was performed using the Cox model.ResultsUsing 2+/3+ as a CD47 positive (CD47pos) expression cut-off, the prevalence of CD47pos expression in NSCLC was 33.0% (63/191), significantly higher than in pulmonary infectious diseases. CD47pos expression was significantly higher in female, non-smoking and adenocarcinoma patients (p=0.020, p<0.001 and p<0.001, respectively). Furthermore, CD47pos expression was significantly correlated with epidermal growth factor receptor mutation (p<0.001). The expression of CD47 (H-score) in NSCLC was negatively correlated with tumour PD-L1 expression (p=0.0346) and tumour mutation burden (p=0.0107). CD47pos expression was independently correlated with poor disease-free survival in patients with resected NSCLC in multivariate Cox regression analysis (p=0.035).ConclusionThis study revealed the demographic, molecular and immuno-microenvironment characteristics of CD47 expression in NSCLC. We identified tumour CD47pos expression as an independent prognostic factor for recurrence in resected NSCLC. Our findings illustrate the potential of anti-CD47 treatment in NSCLC.

The preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer

Surgery Today ◽  
2014 ◽  
Vol 45 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Koichi Fukumoto ◽  
Tetsuo Taniguchi ◽  
Noriyasu Usami ◽  
Koji Kawaguchi ◽  
Takayuki Fukui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
Small Cell Lung ◽  
D Dimer

scholarly journals Circulating Aminopeptidase N/CD13 Is an Independent Prognostic Factor in Patients with Non–Small Cell Lung Cancer

2005 ◽  
Vol 11 (24) ◽  
pp. 8674-8679 ◽  
Author(s):  
Haruyasu Murakami ◽  
Akihito Yokoyama ◽  
Keiichi Kondo ◽  
Shuhei Nakanishi ◽  
Nobuoki Kohno ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
Aminopeptidase N ◽  
Small Cell Lung

Prognostic impact of c-Met/phospho-Met, and topoisomerase I in small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17540-e17540
Author(s):  
Hideko Ikeda ◽  
Hayato Koba ◽  
Koji Kurokawa ◽  
Shingo Nishikawa ◽  
Tomoyuki Araya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Tumor ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
High Expression ◽  
Prognostic Impact ◽  
Small Cell Lung

e17540 Background: The hepatocyte growth factor/MET pathway has been shown to cause tumor progression in several types of carcinomas. We reported that c-Met up-regulated topoisomease I (Topo I) in non-small cell lung cancer cell lines (submitted for publication). The aims of this study were 1) to examine the prognostic influence of c-MET/phospho-MET (p-Met), or Topo I expression and 2) to elucidate correlation between c-Met/p-Met expression and Topo I expression in small cell lung cancer (SCLC). Methods: This retrospective study included 72 SCLC patients (pts) with available tumor tissue from primary lung tumor or metastatic lesions and clinical data including survival. We performed immunohistochemistry to detect c-MET/phospho-MET and Topo I expression. Results: Tumor tissues were obtained from 72 SCLC pts. Sixty-six pts, (51 male, 15 female, median age 67.5 range 43-91, LD/ED 38/28, PS0,1/2,3,4 57/9) were evaluated. c-Met overexpression was seen in 40.9%, p-Met in 74.2%, and Topo I expression in 59.1%, respectively. High expression of Topo I associated with lower response rate (RR) (96.7% in low group vs 78.4% in high group, p=0.029) and shorter progression-free survival (PFS) (65W vs 39W, p=0.040) but did not correlate with overall survival (OS). Phosphorylation of Met protein did not correlate with RR, PFS or OS. Interestingly, intensity of p-Met significantly correlated with Topo I expression (p=0.048). High expression of c-Met protein did not associated with RR or PFS but significantly associated with shorter OS (high 53W, low 95W, p=0.018). Multivariate analysis which included c-Met, stage, PS, and age resulted that c-Met was an independent prognostic factor for OS of pts with SCLC (HR; 2.144, 95% confidence interval 1.162-3.956, p=0.015). Conclusions: This study suggested c-Met high expression was an independent prognostic factor, and Topo I was up-regulated by Met in SCLC.

Sign in / Sign up

Export Citation Format

Share Document